Inherited Creutzfeldt-Jakob disease

For PRNP c.305C>T (p.Pro102Leu), a pathogenic missense variant associated with Gerstmann-Sträussler-Scheinker syndrome (GSS) and the inherited CJD spectrum, antisense oligonucleotide (ASO)-mediated reduction of total PrP levels represents the most promising therapeutic strategy in development. The rationale is based on the principle that prion disease requires PrP substrate — reducing PrP expression below a critical threshold should delay or prevent pathogenic PrP conformational conversion. Ionis Pharmaceuticals has developed ION717, an ASO targeting PRNP mRNA, which has entered clinical trials for genetic prion disease. This approach is variant-agnostic for gain-of-function PRNP mutations, as it reduces total PrP rather than targeting the specific mutation.

Raymond et al. (Lancet Neurol 2019; PMID:31587955) and Bhatt et al. established that PRNP ASOs achieve dose-dependent PrP reduction in prion-infected mice and significantly extend survival. ION717 (Ionis) has entered clinical development for symptomatic and presymptomatic PRNP mutation carriers, based on CSF PrP as a pharmacodynamic biomarker. Minikel et al. (Sci Transl Med 2020; PMID:33268508) demonstrated that heterozygous PRNP loss-of-function is well-tolerated in humans, supporting the safety of partial PrP lowering — individuals with one truncating PRNP allele show no clinical phenotype, providing natural human genetic evidence for target safety. P102L is the most common GSS-associated variant, with autosomal dominant inheritance and variable penetrance. ClinVar classifies it as Pathogenic. The variant destabilizes the PrP globular domain and promotes misfolding into protease-resistant PrPSc conformers. CSF total PrP and RT-QuIC seed amplification serve as established biomarkers for monitoring disease activity and treatment response.

ION717 clinical trial data are preliminary, and no efficacy endpoints have been formally met. ASO delivery requires repeated intrathecal injections — the lifelong treatment burden and procedural risks are substantial. Whether PrP lowering can reverse established neurodegeneration or only slow/prevent further progression is unknown; presymptomatic treatment may be necessary for maximal benefit, but identifying the optimal intervention timepoint in presymptomatic carriers is challenging given variable penetrance and age of onset for P102L (typically 40s-60s but highly variable). Heterozygous PrP reduction may be insufficient if the mutant protein has a particularly high propensity for misfolding. Allele-specific approaches that selectively silence the mutant allele while preserving wild-type PrP could be theoretically superior but are more technically challenging. The extremely low prevalence of genetic prion disease creates challenges for trial enrollment and statistical power.

Antisense oligonucleotide-mediated reduction of total PrP protein is the most clinically advanced therapeutic strategy for PRNP E200K genetic CJD. ION717 (Ionis Pharmaceuticals), administered intrathecally, targets PRNP mRNA to deplete PrP substrate and thereby block prion propagation. The Phase 1/2a PrProfile trial (NCT06153966) has enrolled 56 symptomatic patients across 16 global sites, with a third higher-dose cohort now being added after initial dose regimens showed suboptimal PrP lowering. The substrate-depletion approach is supported by strong genetic evidence: heterozygous PRNP loss-of-function is tolerated in humans, and PrP-knockout mice resist prion infection entirely.

Raymond et al. (2019, PMID: 31361599) demonstrated in prion-infected mice that prophylactic ASO-mediated PrP lowering extended survival by 61–98%, and a single injection near clinical onset extended survival by 55%. Minikel et al. (2020, PMID: 32776089) established that PrP lowering is disease-modifying across multiple prion strains and disease stages. The PrProfile trial completed enrollment in December 2024 with an encouraging safety profile reported as of March 2026. In parallel, a divalent siRNA program (Broad Institute/UMass) received IND clearance from FDA in March 2025 for symptomatic patients, providing a complementary RNA-targeting modality. Base editing (An et al., 2025, PMID: 39810005) achieved 50% PrP reduction and 52% lifespan extension in humanized prion mice via AAV-delivered cytosine base editor, but remains preclinical.

The first two ION717 dosing regimens did not achieve target PrP lowering levels, necessitating dose escalation. Intrathecal delivery requires repeated lumbar punctures every 2–3 months. FDA has placed a partial clinical hold preventing pre-symptomatic dosing, despite the fact that treatment before symptom onset — when irreversible neuronal loss has already begun — is likely to be most effective. E200K penetrance is incomplete (estimated 60–90% depending on population), complicating risk-benefit assessment for presymptomatic carriers. Mean survival from CJD symptom onset is approximately 7.6 months, leaving an extremely narrow treatment window for symptomatic patients. CSF biomarkers (RT-QuIC, PrP levels, NfL) for presymptomatic monitoring are improving but not yet validated for triggering preventive intervention.

Base Editing (BE4max) via AAV9 delivery is a rationale-driven therapeutic strategy for Inherited Creutzfeldt-Jakob disease targeting the PRNP c.385A>G (p.Met129Val) variant (Pathogenic, missense variant, 3 prime UTR variant). The editing system (BE4max (cytosine base editor)) converts the pathogenic C to T (or G to A on the target strand), restoring the wild-type codon. Target tissue: CNS. Therapeutic goal: Correct or durably disrupt pathogenic PRNP alleles at the PRNP locus in the CNS to prevent prion replication and thereby halt or prevent the fatal neurodegeneration of inherited Creutzfeldt-Jakob dise. Risk profile: off-target Medium (bystander bases in editing window), delivery complexity Medium, immunogenicity High (AAV pre-existing immunity).

1. Molecular basis: PRNP NM_000311.5(PRNP):c.385A>G (p.Met129Val) is classified as Pathogenic (ClinVar variation ID 13399). Molecular consequence: missense variant, 3 prime UTR variant. Protein change: M129V, D178N. 2. Epidemiology: Genetic (inherited) prion diseases, including inherited CJD, account for about 10–15% of all human prion diseases (PAPER-01, BIOMNI-07). Overall prion disease incidence is well below 1 per 100,000 person-years, qualifying as ultra-rare (WEB-07). Inherited CJD is an autosomal dominant disorder caused 3. Standard of care: Orphanet and EMA emphasise that there is no curative or disease-modifying therapy for CJD; management is purely supportive and palliative, focused on symptom control (pain, myoclonus, insomnia, anxiety) and comfort care (WEB-02, WEB-04, WEB-08). Patients are often rapidly transitioned to hospice or 4. Pipeline: EMA orphan designations and FDA orphan listings describe several experimental agents for CJD (e.g., pentamer formyl thiophene acetic acid/NSC500 and other small molecules), but none has progressed to marketing approval; NSC500 was only in preclinical evaluation at designation and no trials had start 5. CBE clinical validation: BE4max (Koblan et al. 2018) is the gold-standard cytosine base editor. Multiple CBE programs are in clinical development for liver and hematologic targets.

1. No published data specifically correcting PRNP c.385A>G (p.Met129Val) with Base Editing (BE4max); strategy is based on general principles and must be validated preclinically. 2. PAM availability and bystander base analysis for the specific genomic context have not been performed. If no canonical NGG PAM positions the target within the editing window, PAM-flexible variants (SpRY) may be needed. 4. Delivery to CNS tissue remains a major translational bottleneck. Current vectors have limited transduction efficiency in these compartments. 4. Long-term durability, off-target genome-wide effects, and immunogenicity in the target patient population require thorough preclinical and clinical evaluation.